Roche gets Emergency Use Authorization from USFDA for SARS-CoV-2, Influenza A/B Test
Basel: Roche has recently announced that the cobas® SARS-CoV-2 & Influenza A/B Test for use on the cobas® 6800/8800 Systems has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients suspected by their healthcare provider of having respiratory viral infection consistent with COVID-19. Additionally, it is available in markets accepting the CE mark.
"Roche is committed to delivering as many tests as possible within the limits of supply," Roche stated